登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，3月23日，The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-24

  • The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage

    Jeff Szer, Daniel Weisdorf, Sergio Querol, Lydia Foeken & Alejandro Madrigal

    Bone Marrow Transplantation (2020)

    To the Editor:

    The provision of donors for life-saving hematopoietic stem cell transplants is coordinated through registries and facilitated by the World Marrow Donor Association (WMDA), which operates a global database to find the best stem cell source. The database contains 36,214,535 donors and 790,357 cord blood units from 98 different registries in 53 different countries [1].

  • 原文来源：https://www.nature.com/articles/s41409-020-0873-x
23浏览量
原文链接
相关报告

  • 《LANCET，3月23日，COVID-19 and medical education》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-24
    • COVID-19 and medical education Hanad Ahmed Mohammed Allaf Hussein Elghazaly Published:March 23, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30226-7 The coronavirus disease 2019 (COVID-19) outbreak has rapidly transitioned into a worldwide pandemic. This development has had serious implications for public institutions and raises particular questions for medical schools. Frequent rotations between departments and hospitals make medical students potential vectors for COVID-19. Equally, as trainee doctors we stand to learn a tremendous amount and can contribute to the care of patients, particularly if the UK General Medical Council triggers article 18a of the Medical Student Act (1983).
    121浏览量
    原文链接

  • 《Nature，4月23日，Complement as a target in COVID-19?》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-24
    • Complement as a target in COVID-19? Antonio M. Risitano, Dimitrios C. Mastellos, Markus Huber-Lang, Despina Yancopoulou, Cecilia Garlanda, Fabio Ciceri & John D. Lambris Nature Reviews Immunology (2020) There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients. Most patients who become critically ill following infection with SARS-CoV-2, the causative agent of COVID-19, develop acute respiratory distress syndrome (ARDS)1. The deterioration of lung function has been attributed to a maladaptive immune response rather than increased viral loads. One theory is that the activation of lung-resident immune cells via pattern-recognition receptors drives the release of pro-inflammatory cytokines and extravasation of blood neutrophils and monocytes into the bronchi. These cells may disrupt the air–blood barrier by causing collateral tissue damage, particularly to airway epithelial cells and vascular endothelial cells, which express the ACE2 entry receptor for SARS-CoV-2; the damage of vascular endothelial cells may account for thrombotic microangiopathies.
    107浏览量
    原文链接